TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02371148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib-Rituximab-Bendamustine
Description: Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22\* Rituximab: 375 mg/sqm i.v. day 1\*\* Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles \*In case of toxicity is omitted~\*\*In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8
Study: NCT04213417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath therapy and Matrix Rhythm Therapy
Description: MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath therapy
Description: Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
Study: NCT02501226

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENVIE psychoeducational program
Description: The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference.
Study: NCT02470832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Study: NCT04442984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: d1-2 5-FU 2200 mg/m² every two weeks
Study: NCT02470832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Study: NCT02646657

Intervention type: DRUG
Group type: OTHER
Intervention: Vedolizumab 300 mg
Description: Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46

Intervention type: DRUG
Group type: OTHER
Intervention: Vedolizumab 300 mg
Description: Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
Study: NCT03727269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Fit Training Experimental Group
Description: Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~1. Knack Maneuver (Ashton -Miller 1998, 2008)~2. Pelvic floor strengthening: kegel Exercise.~3. -Lumbo-Pelvic Stabilization Exercise.~4. Functional Training/ PFM Contraction during ADL~5. Correction of biomechanical/structural deformities
Study: NCT03755089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine
Description: 200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: 30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
Study: NCT02586363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude Tab. 0.5mg, fasting
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study: NCT04442984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: d1 5-FU 250 mg/m² every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: d1 Leucovorin 400 mg every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: d1 Leucovorin 400 mg every two weeks
Study: NCT05234996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3 Virtual Reality headset (VR Headset),
Description: The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3 Virtual Reality headset (VR Headset),
Description: The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
Study: NCT01170143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab QW, Trastuzumab Q3W
Description: two arms using Trastuzumab QW vs Q3W
Study: NCT04442984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: d1 5-FU 400 mg/m² every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: d1-2 5-FU 2400 mg/m² every two weeks
Study: NCT03521323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos: Saline，Sham operation
Study: NCT04655118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match TL-895
Study: NCT02510235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricin
Description: Lubricin 150 µg/ml eye drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate 0.13% eye drops
Study: NCT01448291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Description: Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
Study: NCT01180413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
Study: NCT02586363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavir Tab. 0.5mg, fasting
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavir Tab. 0.5mg, high fatty meal
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study: NCT01180413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
Study: NCT02241395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal autologous bone marrow mononuclear cell transplantation
Study: NCT04190784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
Study: NCT02775578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting
Description: Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Coronary Revascularization
Description: Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
Study: NCT04190784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stretching
Description: The therapist maintains the same manual contact without stretching force.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stretching
Description: The therapist maintains the same manual contact without stretching force.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stretching
Description: The therapist maintains the same manual contact without stretching force.
Study: NCT01229488

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Intervention
Description: Project was withdrawn before starting. There were no interventions
Study: NCT04152525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
Study: NCT03707652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement A
Description: 1, 2 or 4 capsules daily of oral supplement A for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement A
Description: 1, 2 or 4 capsules daily of oral supplement A for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement A
Description: 1, 2 or 4 capsules daily of oral supplement A for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement B
Description: 4 capsules daily of oral supplement B for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement B
Description: 4 capsules daily of oral supplement B for 3 days
Study: NCT01102270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: 3mg tablet once prior to sleep
Study: NCT03707652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement C
Description: 1,2 or 4 capsules daily of oral supplement C for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement C
Description: 1,2 or 4 capsules daily of oral supplement C for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement C
Description: 1,2 or 4 capsules daily of oral supplement C for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement D
Description: 1 or 2 tablets daily of oral supplement D for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement D
Description: 1 or 2 tablets daily of oral supplement D for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement D
Description: 1 or 2 tablets daily of oral supplement D for 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement D
Description: 1 or 2 tablets daily of oral supplement D for 3 days
Study: NCT00508040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alpha 2a
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon alpha 2a
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
Study: NCT00697840

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL 208129
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation
Description: Intramuscular injection, 2 doses; experimental formulation
Study: NCT04596397

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient setting
Description: These women stay at the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient setting
Description: These women can leave the hospital.
Study: NCT03795389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Description: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Description: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Description: Single SC dose
Study: NCT02036801

Intervention type: OTHER
Intervention: Lung specific elastance
Description: Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
Study: NCT03707652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Supplement D in combination with oral supplement C
Description: 1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
Study: NCT01102270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule prior to sleep
Study: NCT01720056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Study: NCT00125658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
Study: NCT03408353

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Mammography
Description: Undergo standard of care mammography

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT02551185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Study: NCT01720056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog 10
Study: NCT03086993

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Melphalan/HDS
Description: Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin and Gemcitabine
Description: continuous treatment with Cis/Gem until disease progression
Study: NCT02283619

Intervention type: OTHER
Intervention: None - no intervention, observational study
Description: No intervention, observational study
Study: NCT03663946

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT01633073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme: control device
Description: LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel: comparison device
Description: i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
Study: NCT00900237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eslicarbazepine acetate
Description: Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
Study: NCT02479607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone or tablet